The capital infusion is earmarked for critical infrastructure upgrades to accelerate the development and commercialization of new health technologies. By modernizing the Aurora facility, Piramal intends to ramp up clinical API production and improve operational efficiencies, positioning the site to meet rising global demand for complex drug substances.

Peter DeYoung, CEO of Piramal Global Pharma, noted that the project extends beyond manufacturing capacity to include sustainability and site modernization efforts. The provincial support aligns with Ontario’s broader life sciences strategy, which seeks to turn local research into market-ready medical solutions. Vic Fedeli, Minister of Economic Development, Job Creation and Trade, emphasized that the investment serves to solidify the province’s reputation as a competitive hub for biomanufacturing. The Life Sciences Scale-Up Fund, which received an additional $24 million boost in the 2026 budget, remains a central pillar in the government’s plan to foster domestic healthcare innovation.